Official account of the Hans Messner Allogeneic Blood and Marrow Transplant Program at Princess Margaret Hospital, Toronto. Posts are not medical advice.
Our multidisciplinary team endeavours to provide the highest standards of care. The overarching theme that drives our efforts are to get patients back to their normal lives by treating their diseases, limiting complications (NRM), and preserving quality of life (GRFS).
๐ข Now out in @BrJHaem ๐๐
Our latest work from the @pmcancercentre explores how GvHD prophylaxis influences the risk of second primary malignancies after allogeneic transplants using a large cohort of 1,418 patients (>6000 person-years of follow up)
https://t.co/wCsdX5WDzf
๐ข Published in @ASTCT_Journal ๐
Using a large dataset (@CIBMTR + @Hans_BMTProgram), we show that ATG + PTCy may alleviate the โคด๏ธGvHD risk associated with female donor-to-male recipient MUD transplants ๐๐ฝ
https://t.co/p9epD40RbD
๐ Out now in @ASTCT_Journal ๐๐ฝ
We compare two conditioning regimens for second allogeneic transplant after primary graft failure!
Interesting results ๐๐ฝ
DM me for the PDF!
https://t.co/5ESeV8lPwl @Hans_BMTProgram
Our work is now out in @ASTCT_Journal
We looked into the association between cumulative cyclosporine exposure over the first 90 days (AUC90) post-HCT and key transplant outcomes, including graft failure and relapse.
@Hans_BMTProgram
https://t.co/hWEHnFM6fV
Delighted to share our latest publication on the impact of conditioning intensity in younger AML patients receiving dual T-cell depletion for GVHD prophylaxis.
#Hematology#BMT@AhmedAlNughmush@Hans_BMTProgram
https://t.co/ht6lNaMkmx
๐จ New Study Alert!
@nihardesai89@Haemophage@IvanPasic
Our team retrospectively analyzed our cohort on allogeneic HSCT outcomes in patients with MDS/MPN overlap syndromesโa rare and challenging group of hematologic neoplasms. ๐งต๐
The abstract titles for #ASCO25 are out ๐๐ฝ
We asked 2 questions:
1. Can we โคต๏ธthe PTCy dose in MUDs?
2. What's the outcome of patients who are alive 2 yr post transplant?
We'll answer those questions at the oral abstract session @ASCO#MedTwitter@Hans_BMTProgram
@pmcancercentre Thank you so much for your kind words! ๐
It is truly our privilege to be part of your journey and weโre grateful for the trust you placed in our team. Wishing you continued health and wellness!
๐๐๐Excited to have TWO ORAL PRESENTATIONS at #ASCO25 in Chicago!
As always, I'm thankful to @Haemophage and the team at @pmcancercentre for the phenomenal mentorship ๐๐ฝ
Looking forward to a great discussion and meeting some solid oncologists ๐คฃ
#MedTwitter
Huge milestone!
Today our centre infused the 200th AlloBMT for this fiscal year. Thatโs 200 Allogeneic Stem Cell Transplants THIS YEAR (overall weโre >5k) and weโre still going strong! A new record!
#AlloBMT#bmtsm@pmcancercentre@UHN@nihardesai89@bradwouters@thePMCF